September 6, 2018

HyTest attracts new majority owner

Antibody manufacturer Hytest's growth is driven by an ageing population, innovation and increasing investments in medical care.
Antibody manufacturer Hytest's growth is driven by an ageing population, innovation and increasing investments in medical care.
Screenshot/Hytest

HyTest, a Finnish producer of antibodies and antigens for the diagnostics industry, has a new majority shareholder in Summa Equity.

HyTest’s customer base includes a large number of companies that sell in vitro diagnostics (IVD) equipment, which use antibodies and antigens to diagnose and follow disease development.

“Use of this technology will increase with an ageing population, continued advances in research and technology, and the global trend of increased investments in medical care and wellness,” says Tommi Unkuri, partner at Summa Equity. “HyTest is a globally recognised leader in this space, with a reputation for exceptional quality and innovation. The company has great potential for continued growth, and we look forward to supporting the HyTest team on this journey,”

The Turku-based company has around 100 employees and is active worldwide, including in the US, Asia and Europe. It was founded in 1994 by group of scientists, who are still members of the senior management and will remain as significant shareholders in the company. 

“Our goal since we started has been to improve health, by providing access to the latest research and technology in the arena of antibodies and antigens for diagnostic use to the market,” says Maria Severina, CEO at HyTest. “With Summa Equity as owner, we will be able to take the next step in developing our company, for the benefit of our customers and patients.”

Share: